联系客服

301033 深市 迈普医学


首页 公告 迈普医学:2021年度财务决算报告

迈普医学:2021年度财务决算报告

公告日期:2022-04-21

迈普医学:2021年度财务决算报告 PDF查看PDF原文

 证券代码:301033  证券简称:迈普医学  公告编号:2022-016
          广州迈普再生医学科技股份有限公司

                2021 年度财务决算报告

    一、2021 年度公司财务报表审计情况

    广州迈普再生医学科技股份有限公司 2021 年度财务报表,经华
 兴会计师事务所(特殊普通合伙)审计,并出具了华兴审字 [2022]22000510013 号标准无保留意见的审计报告。

    二、关键财务指标

        项目              2021 年          2020 年        同比增减

应收账款周转率                  23.13            20.12        14.95%

存货周转率                        1.41              1.24        14.03%

经营活动产生的现金流量  66,510,692.29    33,908,754.88        96.15%
净额(元)

基本每股收益(元/股)            0.79              0.75        5.33%

加权平均净资产收益率            10.23%            11.64%        -1.41%

资产总额(元)          746,569,716.44    447,939,659.82        66.67%

归属于上市公司股东的净  572,042,384.19    335,995,919.55        70.25%
资产(元)

资产负债率                      22.89%            24.18%        -1.28%

    三、主要财务数据


      2021 年度公司实现营业收入 15,378.57 万元,较去年同期增长
  24.51%;营业利润为 4,371.40 万元,较去年同期增长 10.49%;利润
  总额为 5,159.98 万元,较去年同期增长 19.99%;归属上市公司股东
  的净利润为 4,473.38 万元,较去年同期增长 21.01%。

      1、2021 年度经营情况变动及说明

                                                          单位:万元

    项目        2021 年    2020 年    同比增减    重大变动说明

营业收入        15,378.57  12,351.18    24.51%

                                                    主要系颅颌面修补系
                                                    统销售增长较快、占
                                                    比上升,其毛利率低
营业成本          2,708.81  2,040.35    32.76% 于人工硬脑(脊)膜
                                                    补片,导致总体成本
                                                    增长高于总体收入增
                                                    长

销售费用          4,859.42  4,012.33    21.11%

管理费用          2,441.00  1,950.47    25.15%

研发费用          2,587.54  1,627.96    58.94% 主要系本报告期研发
                                                    项目投入增加所致

                                                    主要系本报告期适用
财务费用            68.24      20.14    238.78% 新租赁准则,将租赁
                                                    负债未确认融资费用
                                                    确认为利息费用所致

公允价值变动                                      主要系本报告期公司
收益                97.96      40.10    144.32% 购买理财产品公允价
                                                    值变动所致

投资收益            609.70    489.22    24.63%

其他收益          1,032.31    877.32    17.67%

营业外收入          801.41    409.27    95.82% 主要系本报告期收到
                                                    上市补助所致

      2、2021 年末资产负债表项目变动及说明

                                                            单位:万元

项目            2021 年 12  2020 年 12  同比增减  重大变动说明

                月 31 日    月 31 日

货币资金          1,035.19    1,169.10    -11.45%

交易性金融资产  37,557.15  19,933.31    88.41% 主要系本报告期购买
                                                  理财产品增加所致

应收账款            531.91      774.54    -31.33% 主要系本报告期应收
                                                  账款回款改善所致

                                                  主要系上年预付上市
预付款项            268.12      923.62    -70.97% 中介机构费用,本报
                                                  告期确认为发行费用
                                                  所致

其他应收款          139.89      122.92    13.81%

存货              2,117.73    1,653.15    28.10%

                                                  主要系本报告期内不
其他流动资产        64.23      679.30    -90.54% 再购买承诺保本保收
                                                  益情形的理财产品所
                                                  致

固定资产          2,192.47    2,062.79      6.29%

在建工程        20,194.63    9,735.45    107.43% 主要系总部基地项目
                                                  建设增加所致

使用权资产          758.99                      -

                                                  主要系本报告期可吸
                                                  收再生氧化纤维素国
无形资产          5,465.92    3,161.71    72.88% 内注册证申请获批,
                                                  该项目开发支出转入
                                                  无形资产所致

                                                  主要系本报告期可吸
                                                  收再生氧化纤维素国
开发支出          2,155.26    3,132.48    -31.20% 内注册证申请获批,
                                                  该项目开发支出转入
                                                  无形资产所致

长期待摊费用        560.70      710.59    -21.09%

                                                  主要系子公司本报告
递延所得税资产      402.81      669.49    -39.83% 期盈利导致可弥补亏
                                                  损减少所致

                                                  主要系本报告期增加
其他非流动资产    1,211.99      65.52  1,749.91% 预付的长期资产采购
                                                  款项所致

应付账款          3,273.40    3,664.67    -10.68%


项目            2021 年 12  2020 年 12  同比增减  重大变动说明

                月 31 日    月 31 日

预收款项            39.47      53.48    -26.19%

合同负债            46.61      335.19    -86.09% 主要系本报告期订单
                                                  执行率较高所致

应付职工薪酬      1,288.16    1,109.05    16.15%

应交税费            338.01      304.17    11.12%

其他应付款          186.34      140.
[点击查看PDF原文]